Journal
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
Volume 114, Issue 1, Pages 13-17Publisher
WILEY
DOI: 10.1111/bcpt.12157
Keywords
-
Categories
Funding
- Swedish Research Council
- Swedish Foundation for Strategic Research
- King Gustaf V:s 80-year's Foundation
- Karolinska Institutet
- Swedish Rheumatism Association
Ask authors/readers for more resources
Anticitrullinated protein antibodies (ACPAs) constitute a class of autoantibodies found in 60-70% of patients with rheumatoid arthritis (RA). The most common test for ACPA positivity is based on the occurrence of antibodies that bind to circular citrullinated peptides, so-called CCP, some of which are derived from endogenously citrullinated proteins, like filaggrin. Several lines of evidence suggest that these autoantibodies may confer pathological reactions. They appear years before onset of clinical disease and are associated with worse prognosis and a more erosive disease. Their presence correlates with the most prominent genetic risk factors for RA development, and they were recently described to mediate relevant biological functions such as activation of complement system and induction of osteoclastogenesis. The development of new drugs that specifically target these autoantibodies is an appealing and novel approach. Herein, we briefly review the autoimmune condition of RA, characterized by the presence of ACPA, and we describe how the neutralization of autoantibodies might become a novel pharmacological principle.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available